Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:57:37 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:SPRO from 2023-05-04 to 2024-05-03 - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 16:08U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-13 16:01U:SPRONews ReleaseSpero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
2024-03-06 08:05U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
2024-02-28 08:05U:SPRONews ReleaseSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
2024-02-26 08:05U:SPRONews ReleaseSpero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference
2024-01-31 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 08:05U:SPRONews ReleaseSpero Therapeutics Provides Corporate Update and 2024 Outlook
2024-01-02 08:05U:SPRONews ReleaseSpero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial ‚  Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
2023-11-13 16:05U:SPRONews ReleaseSpero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
2023-11-06 08:05U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
2023-11-01 16:05U:SPRONews ReleaseSpero Therapeutics to Present at Upcoming November Investor Conferences
2023-11-01 08:05U:SPRONews ReleaseSpero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
2023-10-31 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-29 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-20 16:05U:SPRONews ReleaseSpero Therapeutics to Present at Cantor ¢ € ™s Global Healthcare 2023 Investor Conference
2023-09-12 08:00U:SPRONews ReleaseSensorium Therapeutics Appoints Veteran Life Sciences Executive ‚  Mr. David Southwell to its Board of Directors
2023-09-06 08:05U:SPRONews ReleaseSpero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-31 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-10 16:05U:SPRONews ReleaseSpero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
2023-08-03 08:05U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
2023-07-31 08:05U:SPRONews ReleaseSpero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
2023-06-30 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-14 08:05U:SPRONews ReleaseSpero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
2023-05-31 16:05U:SPRONews ReleaseSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-11 16:05U:SPRONews ReleaseSpero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update
2023-05-04 08:05U:SPRONews ReleaseSpero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023